The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Some medtech stocks did decline in 2018, but many more increased in value.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.